Arcturus Therapeutics Holdings Inc. — Form 10-Q
Filed August 6, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 42/100
What the filing says
Arcturus signed a Master Services Agreement (MSA) with Thermo Fisher Scientific dated June 26, 2026, establishing a $40 million manufacturing cap for clinical manufacturing services for ARCT-032 Phase 3 trial, matched by a $40 million commitment to Thermo Fisher's PPD affiliate for CRO services. The agreement includes a risk-sharing side agreement granting Thermo Fisher commercial manufacturing exclusivity post-approval for a defined term, with preliminary commercial pricing in Exhibit A-2 (redacted). Arcturus also executed a separate manufacturing project agreement with Patheon UK Limited for bulk drug product and drug product fill-and-finish services with costs heavily redacted.
Why this rating
Material partnership for ARCT-032 development (~12% of market cap in committed spend), but structure is typical for biotech Phase 3 financing. Significance tempered by redactions preventing full cost/risk assessment.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.